Ceftobiprole, an investigational parenteral cephalosporin in phase 3 clinical trials, exhibits a broad spectrum of activity against many clinically important gram-negative and grampositive bacteria (3, 4, 7, 18, 20, 21, 29) . Ceftobiprole is distinguished from other marketed ␤-lactams by its increased binding to penicillin-binding protein (PBP) 2a (PBP2a) from methicillin-resistant staphylococci (18, 24) .
PBPs, the targets of ␤-lactam antibiotics, are membraneassociated enzymes involved in the last steps of peptidoglycan biosynthesis. The affinities of ceftobiprole for PBPs from Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae were determined.
(This work was presented in part at the 106th General Meeting of the American Society for Microbiology, Orlando MICs were determined according to CLSI methods (5) using Trek Diagnostic Systems (Cleveland, OH) panels, except for ceftobiprole, which was prepared fresh for each assay. E. coli, P. aeruginosa, or S. aureus PBPs were isolated as described previously (18, 30) . For S. pneumoniae, whole cells were used. PBPs were labeled with Bocillin FL (Invitrogen, Carlsbad, CA) as described previously (26). S. aureus OC 3726 membranes were preincubated with 1 mg/ml clavulanic acid (USP, Rockville, MD) to saturate all PBPs except PBP2a. PBPs were visualized using a LumiImager (Roche, Indianapolis, IN), and 50% inhibitory concentration (IC 50 ) values were determined using Quantity One software (Bio-Rad, Hercules, CA). P. aeruginosa cell morphology after ceftobiprole exposure was monitored by microscopic examination at a magnification of ϫ1,000. S. pneumoniae pbp1a, pbp2x, and pbp2b were amplified by PCR as described previously (23) and sequenced by ACGT (Wheeling, IL).
For E. coli MC4100, all drugs had good affinity for PBP3, the primary target for monobactams and most cephalosporins (10, 12) (Table 1) . Ceftobiprole, ceftriaxone, and cefepime also had good affinity for the essential PBP2 (IC 50 s of Յ0.6 g/ml) ( Table 1 ). However, they were at least 20-fold less potent than imipenem (Table 1) , for which the primary target is PBP2 in gram-negative bacteria (28) . Ceftobiprole and ceftriaxone had IC 50 s for PBP1a and PBP4 that were approximately 5-to 10-fold lower than those for cefepime and ceftazidime (Table  1 ). Ceftriaxone and imipenem had greater affinity for PBP1b than the other drugs (Table 1) . Only imipenem had high affinity for the nonessential PBP5 and PBP6 (Table 1) . Cephalosporins like cefotaxime and ceftazidime target primarily PBP3 and have at least a 50-fold-lower affinity for PBP2 (6, 17, 25) . Conversely, the increased affinity of ceftriaxone and cefepime for PBP2 compared to those of other cephalosporins (9, 14, 25) was confirmed in this study and also observed for ceftobiprole (Table 1) .
For P. aeruginosa PAO1, the cephalosporins had the greatest affinity for PBP1a and PBP3 (Table 1 ). Ceftobiprole and cefepime had approximately a 10-fold-higher affinity for PBP4 than ceftazidime (Table 1 ). Ceftobiprole and imipenem had the lowest IC 50 values for PBP1b. Imipenem had the highest affinity for PBP2 (IC 50 of 0.1 g/ml), with ceftobiprole having the greatest affinity (IC 50 of 3 g/ml) among the cephalosporins (Table 1) . Cefepime and ceftazidime bound PBP2 with at least an 80-fold-lower affinity than that for PBP3, similar to previously reported data (17, 25) . Conversely, ceftobiprole had measurable affinity for PBP2, with an IC 50 value 30-fold higher than that for PBP3. The cephalosporins did not bind to PBP5/6 at concentrations as high as 32 g/ml (Table 1) . Aztreonam had highest affinity for PBP3 (Table 1) . P. aeruginosa cells grown in the presence of ceftobiprole produced filamentation (Fig. 1) , suggesting that PBP3 was the primary target.
In methicillin-susceptible S. aureus ATCC 29213, ceftobiprole had good affinity (IC 50 of Յ1 g/ml) for all four PBPs (Table 2 ). Ceftobiprole had the greatest affinity for PBP3, with an IC 50 that was 20-fold lower than that of ceftriaxone. Inhibition of this PBP leads to cell enlargement and the termination of septation (11) . Ceftobiprole had better affinity than ceftriaxone for all PBPs except PBP2 (Table 2) , whose inhibition leads to cell lysis (11) .
PBP2a from methicillin-resistant S. aureus strain OC 3726 (Table 2 and Fig. 2 ) had high affinity for ceftobiprole, unlike ceftriaxone and ceftazidime. Entenza et al. previously reported low ceftobiprole IC 50 s for PBP2a (Յ0.47 g/ml), which were Ͼ100 times lower than those for methicillin (8) . Hebeisen et al. also reported potent binding of ceftobiprole to PBP2a from S. epidermidis (18) .
S. pneumoniae OC 8865 was penicillin susceptible and had no pbp1a, pbp2b, and pbp2x mutations. Ceftobiprole and ceftriaxone PBP-binding profiles were similar (Table 2) , having high affinity for PBP1a and PBP2x, the primary cephalosporin targets (13, 22) . Unexpectedly, ceftobiprole had good affinity for PBP2b (IC 50 value of 0.06 g/ml), unlike ceftriaxone, which had an IC 50 of Ͼ1 g/ml (Table 2 ). Studies have shown that a Concentration of ␤-lactam that inhibits 50% of Bocillin FL binding to that PBP compared to a no-drug control. For E. coli MC4100, 10 concentrations of each drug ranging from 0.016 g/ml to 8 g/ml were used in the competition assay, and for P. aeruginosa, 10 concentrations ranging from 0.06 g/ml to 32 g/ml were used.
b MIC in g/ml. c ND, not determined.
FIG. 1. P. aeruginosa PAO1 grown for 1.5 h in (A) nutrient broth alone (control) or (B) nutrient broth containing 1 g/ml ceftobiprole (1ϫ MIC). Magnification, ϫ1,000. a Concentration of ␤-lactam that inhibits 50% of Bocillin FL binding to that PBP compared to a no-drug control. The following concentration ranges of each drug were used in the competition assays for the following organisms: S aureus ATCC 29213, 0.001 g/ml to 50 g/ml; S. aureus OC 3726, 0.16 g/ml to 50 g/ml; S. pneumoniae OC 8865, 0.004 g/ml to 1 g/ml; and S. pneumoniae OC 8819, 0.06 g/ml to 8 g/ml.
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cefotaxime, ceftriaxone, cefuroxime, and ceftazidime have poor affinity for PBP2b (13, 16, 22) . The ceftobiprole affinity for PBP2b may be due to improved kinetic interactions as seen with the methicillin-resistant staphylococcus PBP2a (18) . In pneumococcal clinical isolates, ␤-lactam resistance is caused primarily by alterations in PBP1a, PBP2x, and PBP2b (1, 2, 15, 27) . Penicillin-and ceftriaxone-resistant S. pneumoniae OC 8819 had the following substitutions: T371S to S and P432 to T in PBP1a; T338 to A, M339 to F, I371 to T, R384 to G, M400 to T, and L546 to V in PBP2x; and T446 to A and A619 to G in PBP2b. For PBP2x, ceftobiprole had an eightfold-higher binding affinity than ceftriaxone (Table 2) . HeinzeKrauss et al. similarly reported that a ceftobiprole analog had IC 50 values that were approximately sixfold lower than those of ceftriaxone against purified PBP2x from two cefotaxime-resistant isolates (19) . Neither ceftobiprole nor ceftriaxone bound to PBP2b at concentrations of Յ8 g/ml (Table 2) , which was probably due to the PBP2b T446-to-A substitution known to contribute to penicillin resistance (13) . Affinities for PBP1a, PBP2a, and PBP3 were similar for both drugs, but ceftriaxone had a higher affinity for PBP1b than did ceftobiprole (Table 2) .
In summary, ceftobiprole demonstrated potent binding to PBPs from gram-positive bacteria, including those with decreased ␤-lactam sensitivity, such as PBP2a in MRSA and PBP2x in a penicillin-resistant S. pneumoniae strain, in contrast to ceftriaxone. In E. coli, ceftobiprole exhibited strong binding to the essential PBPs PBP2 and PBP3. Ceftobiprole exhibited a binding profile similar to those of cefepime and ceftazidime in P. aeruginosa but with enhanced binding to PBP2. These binding profiles explain the broad-spectrum activity for ceftobiprole that includes gram-negative bacteria and many ␤-lactam-resistant gram-positive cocci, including MRSA. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J. Antimicrob. 
